Common Stock:

3 Months Ended

Mar. 31, 2016

STOCKHOLDERS' EQUITY [Abstract]

Stockholders Equity Note Disclosure [Text Block]

Note 8 – Common Stock:

During the three months ended March 31, 2016, three holders of 1,050 total shares of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share converted those shares into 105,000 shares of Neurotrope’s Common Stock and two holders of 2,619 warrants exercisable at $0.01 per share of Common Stock exercised their warrants into 2,619 shares of Common Stock

On April 12, 2016, the stockholders of the Company approved to increase the number of authorized shares of our Common Stock to 400,000,000 shares (See Footnote 11 - “Subsequent Events”.)